Iran J Pharm Res. 2013;12(3):471-81.

Biological evaluation of a siliconized analog of clofibrate (silafibrate) in rodents.

Iranian journal of pharmaceutical research : IJPR

Mojtaba Ziaee, Mohammad Ali Eghbal, Jafar Rahmani, Mohammad Ghaffarzadeh, Arash Khorrami, Alireza Garjani

PMID: 24250653 PMCID: PMC3813287

Abstract

Silicon is the element very similar to carbon, and bioactive siliconized compounds have therefore received much attention. Siliconization of a compound enhances its biological activities. In the present study the hypolipidemic effect and toxicity of clofibrate and its siliconized analog, silafibrate, were compared. The experiments were performed in hypercholesterolemicWistar rats. Animals received high fat diet with 62.75% normal chow, 2% cholesterol, 0.25% cholic acid, 15% lard oil, 10% wheat flour and 10% sucrose.Silafibrate(40 mg/kg/day) produced a predominant reduction in the serum levels of total cholesterol (28.4%, p < 0.001), triglycerides (62%, p < 0.0001) and low-density lipoproteins (27%, p < 0.001) being more effective than the reference drug clofibrate (20%, 40%, 14.5%; p < 0.05). Similarly, it increased the total antioxidant levels in serum by 40% (p < 0.05). Simultaneously, treatment with silafibrate also reduced the malondialdehyde(MDA) concentration by 41% (p < 0.05). LD50 of silafibrate, given orally,was greater than 2000 mg/kg body weight inalbino mice while LD50 for clofibrate was calculated to be 1220 mg/kg. Thirty-day subacute toxicity was also evaluated with oral daily dose at 25, 50 and 100 mg/kg body weight in Wistarrats. No significant changes in body weight, food intake, behavior, mortality, hematology, blood biochemistry, vital organ weight were detected. The results of this study indicate that the effectiveness and safety of thehypolipidemic drug, clofibrate, were enhanced remarkably by replacing chlorine atom in its phenoxy ring with trimethylsilyl.

Keywords: Clofibrate; Hypolipidemicdrug; Silafibrate; Siliconizedanalog; Toxicity

References

1. Iran J Pharm Res. 2012 Winter;11(1):91-5 - PubMed
2. J Ethnopharmacol. 2010 Mar 2;128(1):236-40 - PubMed
3. Curr Opin Drug Discov Devel. 2003 Jul;6(4):526-43 - PubMed
4. Atherosclerosis. 1998 Jun;138(2):271-80 - PubMed
5. Lipids. 1999 May;34(5):497-502 - PubMed
6. Rev Med Chil. 2008 Jun;136(6):775-82 - PubMed
7. Clin Biochem. 2008 Aug;41(12):1002-7 - PubMed
8. Chem Pharm Bull (Tokyo). 1984 Apr;32(4):1568-77 - PubMed
9. J Appl Physiol (1985). 2001 Nov;91(5):2005-9 - PubMed
10. Hum Exp Toxicol. 2001 May;20(5):243-9 - PubMed
11. Nature. 2000 May 25;405(6785):421-4 - PubMed
12. Hypertension. 2005 Nov;46(5):1086-92 - PubMed
13. Mol Endocrinol. 1997 Jun;11(6):779-91 - PubMed
14. Bioorg Med Chem. 2007 Jul 15;15(14):4674-99 - PubMed
15. Lancet. 2005 Jan 29-Feb 4;365(9457):417-30 - PubMed
16. J Clin Pathol. 2002 Nov;55(11):859-61 - PubMed
17. Toxicol Sci. 2010 Jul;116(1):67-78 - PubMed
18. Curr Opin Drug Discov Devel. 2007 Nov;10(6):654-71 - PubMed
19. Clin Chem. 2003 Apr;49(4):690-2 - PubMed
20. Drug Metab Dispos. 2010 Jan;38(1):73-83 - PubMed
21. Exp Diabetes Res. 2010;2010:828531 - PubMed
22. FASEB J. 1995 Feb;9(2):200-9 - PubMed
23. Eur J Med Chem. 2009 Oct;44(10):3973-80 - PubMed
24. Am J Clin Pathol. 1951 Mar;21(3):275-81 - PubMed
25. Nature. 1996 Nov 7;384(6604):39-43 - PubMed

Publication Types

• Journal Article